Ligand Pharmaceuticals Inc. (LGND) earnings: date, estimates and history
Price $304.49 · data as of November 16, 2026
Next earnings report
The date appears here once Ligand Pharmaceuticals confirms it, usually two to four weeks before the report.
Track record
Ligand Pharmaceuticals beat the consensus earnings estimate in 4 of its last 5 reports, by +24.4% on average. On report days the stock moved 3.7% on average, up or down.
Earnings history
| Reported | EPS estimate | EPS actual | Surprise | Revenue | Revenue growth | Stock move |
|---|---|---|---|---|---|---|
| October 29, 2026 Sep/2026 | $2.33 | $2.67 | +14.7% | $79M | — | −0.4% |
| August 6, 2026 Jun/2026 | $1.95 | $2.37 | +21.5% | $64M | +33.7% | −3.1% |
| May 7, 2026 Mar/2026 | $1.80 | $1.63 | −9.6% | $52M | +14.1% | −4.8% |
| February 26, 2026 Dec/2025 | $1.50 | $2.02 | +34.9% | $60M | +39.4% | +3.6% |
| November 6, 2025 Sep/2025 | $1.93 | $3.09 | +60.5% | $115M | +122.8% | +6.4% |
EPS as compared with analyst estimates (adjusted EPS). Revenue growth is against the same quarter a year earlier. Stock move: change on the first trading day after the report.
Frequently asked questions
When is Ligand Pharmaceuticals’s next earnings date?
Ligand Pharmaceuticals has not confirmed its next report date yet. Its last report was on October 29, 2026.
Did Ligand Pharmaceuticals beat earnings last quarter?
Yes, it reported EPS of $2.67 on October 29, 2026 against an estimate of $2.33 (a +14.7% surprise), and the stock moved −0.4% the next trading day.
What EPS do analysts expect next quarter?
The consensus estimate is $2.88 per share on revenue of about $98M.
Report dates and estimates from analyst consensus data; results from company reports. Updated daily. Not investment advice. Earnings calendar